2022
Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial
Oka S, Yamaki T, Sasaki M, Ukai R, Takemura M, Yokoyama T, Kataoka-Sasaki Y, Onodera R, Ito YM, Kobayashi S, Kocsis JD, Iwadate Y, Honmou O. Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial. JMIR Research Protocols 2022, 11: e37898. PMID: 35793128, PMCID: PMC9301565, DOI: 10.2196/37898.Peer-Reviewed Original ResearchChronic brain injuryAutologous mesenchymal stem cellsSpinal cord injuryINTERNATIONAL REGISTERED REPORT IDENTIFIERBrain injuryIntravenous infusionRankin Scale gradesCord injuryMesenchymal stem cellsClinical trialsScale gradeTherapeutic efficacyJapan Medical Association CenterSapporo Medical University HospitalInvestigator-initiated clinical trialsModified Rankin Scale gradesOpen-label trialPhase 2 studyPhase 2 trialMedical University HospitalCause of disabilityMotor vehicle accidentsPotential therapeutic efficacyProportion of casesStem cells
2021
Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series
Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, Kato J, Sasaki Y, Ishiai S, Ito YM, Namioka A, Namioka T, Nakazaki M, Kataoka-Sasaki Y, Onodera R, Oka S, Sasaki M, Waxman SG, Kocsis JD. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clinical Neurology And Neurosurgery 2021, 203: 106565. PMID: 33667953, DOI: 10.1016/j.clineuro.2021.106565.Peer-Reviewed Original ResearchConceptsSpinal cord injuryAmerican Spinal Injury Association Impairment ScaleMSC infusionAutologous mesenchymal stem cellsASIA CASIA DIntravenous infusionMesenchymal stem cellsSCI patientsFunctional statusFunctional improvementSpinal cord injury patientsSpinal Cord Independence MeasureASIA B patientsASIA C patientsPhase 2 studySerious adverse eventsCord injury patientsCurrent therapeutic optionsStem cellsASIA BASIA gradeC patientsNeurologic improvementAdverse events